NCT01065051

Hemodynamic and Echocardiographic Assessment of Riociguat Effects on Myocardial Wall Contractility and Relaxation Kinetics

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of a Single Dose of 1 mg Riociguat (BAY63-2521) on Myocardial Contractility and Relaxation in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (PH-sLVD)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to assess whether oral Riociguat affects the left ventricular contractility and relaxation in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

Detailed description

Adverse event data will be covered in Adverse events section.

Conditions

• Hypertension, Pulmonary
• Ventricular Dysfunction, Left

Interventions

Type	Name	Description
DRUG	Riociguat (Adempas, BAY63-2521)	1 mg single oral dose
DRUG	Placebo	Single oral dose

Timeline

• Start date: 2010-11-01
• Primary completion: 2011-01-01
• Completion: 2011-01-01
• First posted: 2010-02-09
• Last updated: 2014-01-06
• Results posted: 2014-01-06

Locations

2 sites across 1 country: United States